A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

A. M. Evens, K. R. Carson, J. Kolesar, C. Nabhan, I. Helenowski, N. Islam, B. Jovanovic, P. M. Barr, P. F. Caimi, S. A. Gregory, L. I. Gordon

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Fingerprint

Dive into the research topics of 'A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Neuroscience